Obesity drugs improve heart health: Study shows additional benefits of semaglutide and tirzepatide We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Medical Bulletin 12/November/2025 We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Explainer video: Advise- Educating Patients about Addressing Glycemic and Weight Goals We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
President Trump last week hailed his deal with pharma companies to cut the price of blockbuster weight loss drugs as a major win for his administration and for increasing drug affordability. The question is how big of a difference the agreement will make for patients. The deal is expected to significantly expand access to GLP-1…
Eloralintide-Long-Acting Amylin Receptor Agonist Shows Significant Weight Loss in Obesity in a Phase 2 Trial We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
WASHINGTON — The Trump administration is nearing deals with Eli Lilly and Novo Nordisk to lower the prices of their weight loss drugs and expand access to them, people familiar with the talks told STAT. The companies have been close to a deal for weeks, one lobbyist with knowledge of the negotiations said, echoing others who…
Metsera said Tuesday that Pfizer and Novo Nordisk both upped their bids to acquire the obesity startup, with Novo’s offer coming in higher, valuing the company for up to $10 billion. Under Novo’s new proposal, it would pay $62.20 per share in exchange for half of Metsera’s shares upon signing the deal (up from its…
As pharma companies and President Trump tout initiatives to sell branded medications directly to cash-paying consumers, some entrepreneurs have seized on a potential business opportunity — pitching a new model for employers to help their workers pay for medications without using insurance. Take the blockbuster obesity treatments Wegovy and Zepbound, for example. Many employers don’t…
A groundbreaking study published in Hypertension, the journal of the American Heart Association, has identified a set of blood-based biomarkers that can predict improvements in blood pressure five years after adolescents underwent metabolic bariatric surgery. This is the first study to demonstrate that measures of a patient’s unique biological profile taken before weight loss surgery…
Time-Restricted Eating Matches Calorie Restriction in Weight Loss with Better Adherence and Safety among women: Study We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link